Victory is in sight! The EU is in a position to approve the merger of Mylan and Pfizer Upjohn.

On April 22nd the European Commission announced the approval of the merger of Upjohn and Mylan.
subject to approval, some of Mylan's generics businesswill will be stripped.
the merger of the two companies was originally proposed in July 2019, but has since been tested by the antitrust act and the COVID-19 outbreak.
often the most important concern of antitrust laws is the sale of competitive assets in the combined portfolio of drug manufacturers, which would lead to a certain market monopoly.
late last month, foreign media reported that Mylan and Pfizer had agreed to back down on some of the censorship in an effort to remove obstacles to the antitrust bill.
Related Read: Continue To Merge, Pfizer and Mylan Make Concessions! Recently, the European Commission finally completed the investigation of the merger, and agreed to the implementation of the merger. "The EU will ensure that the merger does not harm competition and reserves competitive access to certain generic drugs for the health sector and European citizens," said Margrethe Vestager, executive vice president of competition policy at the
EU.
" is understood to be focusing on generic drug markets sold to hospitals and pharmacies.
the market, Mylan and Upjohn overlap in the treatment areas of cardiovascular, reproductive urology, musculoskeletal, nervous system and sensory organs.
survey found that most of the products offered by Mylan and Upjohn did not cause competition problems.
However, in some countries and regions, there are local market competition concerns for 36 small-molecule drugs, including Atorvastatin, due to the strong position of the two companies and the limited number of key competitors in the market.
to address these issues, Mylan and Upjohn propose to sell Mylan's operations in the relevant markets, including effective distribution authorizations, contracts and brands, and short-term manufacturing and supply arrangements, to one or more suitable buyers, covering certain generics in 20 countries across the European economy and the UK. the
Commission also investigated the vertical relationship between Mylan and Upjohn in relation to the authorized transfer of active drug ingredients and generics upstream.
concluded that there was no warning about market competition in this regard.
the merger between the two companies, Mylan has more than 7,500 product portfolios, including biosimilars, generics, branded and over-the-counter drugs, while providing API and manufacturing and supply chain advantages.
Upjohn has a range of iconic brand drugs in the field of noncommunicable diseases, such as Lipto, Cierce and Van Aico, and has a strong commercialization capability.
the two companies have a greater potential advantage in terms of product and business capabilities when integrated.
industry reports said the merger was in response to an increasein competition in India's generic drug market.
the deal, worth about $63bn, was expected to close early this year, but the review slowed down due to global panic over the new crown virus, and Mylan announced last month that the merger would be delayed until the second half of this year.
Source: 1, EU approves merger of Pfizer off-patent unit and Mylan 2, Mergers: Commission approves the merger of Mylan and Pfizer's Upjohn division, to the contents.